AACE’s Improving Obesity Diagnosis and Treatment through Endocrinology and Primary Care Collaboration is designed to equip primary care physicians, physicians in-training, nurse practitioners, physician assistants, registered dietitians, nurses, and other health care providers with evidence-based knowledge to foster the understanding of obesity as a complex, chronic, progressive, and treatable multi-factorial, neurobehavioral disease, and provides treatment strategies, including information on the safety and effectiveness of anti-obesity medications (AOMs) as adjuncts to lifestyle modifications and bariatric procedures.

This program includes multiple activities that allow for high levels of learner involvement, interactivity, feedback, and a focus on a case-based approach. These include:

Four presentations:

1. Obesity Diagnosis and Pathophysiology

2. Starting the Journey to Healthy Weight (Overcoming Stigma and Barriers)

3. How to Start Treating Obesity in the Office

4. Advanced Therapeutics for Obesity Beyond Lifestyle Interventions

Three “Patient Conversations” providing case-based examples for patient communication.

1. Lifestyle-based Weight Management Patient Conversation

2. Obesity Treatment: Surgical Options Patient Conversation

3. Obesity Treatment: Medication-based Patient Conversation

A patient video to provide insight on provider/patient interaction from the patient perspective.

Self-Assessment style patient cases to test your knowledge.

• Recognize obesity as a chronic, serious disease warranting diagnosis, long-term management, and early intervention to minimize associated comorbidities and psychosocial health consequences. 
• Identify the biological basis of obesity including the role of genetics and hormones on appetite and energy regulation, metabolic adaptation to weight loss, and cardiometabolic risk factors. 
• Destigmatize obesity to initiate and enhance patient engagement in healthy weight conversations and facilitate discussions on evidence-based obesity treatments in healthcare settings. 
• Manage obesity with shared decision making, including AOM pharmacotherapy, bariatric surgery, behavior, and lifestyle interventions to achieve and maintain clinically meaningful, long-term weight loss. 

• Implement strategies that lead to improved patient adherence in obesity care.

• Primary care physicians (PCPs)
• Physicians in-training
• Nurse practitioners (NPs)
• Physician assistants (PAs)
• Registered dietitians (RDs)
• Nurses
• Other health care providers (HCPs).

• Monica Agarwal, MD, FACE, MEHP - Nothing to Disclose
• Jaime Almandoz, MD  - NovoNordisk, Eli Lilly - Advisory Boards
• Sandhya Bassin, MD  - Nothing to Disclose
• Lissa Bauer, MD, FACP  - Nothing to Disclose
• Karla Saint Andre, MD  - Rythm, Novartis, Karyopharm, Pacific, Viatris, Novo, Rockley, Amgen - Stocks 
• Diane Alberson, MEd, CAE - Nothing to Disclose

• Brandi Addison, DO, FACE  - Nothing to Disclose
• Jaime Almandoz, MD  - NovoNordisk, Eli Lilly - Advisory Boards
• Sandhya Bassin, MD  - Nothing to Disclose
• Lissa Bauer, MD, FACP  - Nothing to Disclose
• Karla Saint Andre, MD  - Rythm, Novartis, Karyopharm, Pacific, Viatris, Novo, Rockley, Amgen - Stocks 

This activity is supported by independent educational grants from Eli Lilly and Rhythm Pharmaceuticals.

• Brandi Addison, DO, FACE, Endocrinology Course Director, South Texas Endocrinology & Metabolism Center, PLLC
• Monica Agarwal, MD, FACE, MEHP, Professor, University of Alabama at Birmingham 
• Jaime Almandoz, MD, MBA, FTOS, MRCPI, Medical Director, University of Texas Southwestern Medical Center
• Sandhya Bassin, MD, Endocrinology Fellow, Icahn School of Medicine and Mount Sinai
• Lissa Bauer, MD, FACP, Assistant Professor, Naval Medical Center San Diego
• Karla Saint Andre, MD, Endocrinologist, Houston Methodist Hospital

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.